Business Description
Alaunos Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US98973P1012
Share Class Description:
STU:WEK: Ordinary SharesDescription
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations.
Financial Strength
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 3.54 | |||||
| Equity-to-Asset | 0.8 | |||||
| Debt-to-Equity | 0.24 | |||||
| Debt-to-EBITDA | -0.05 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -217.49 | |||||
| Beneish M-Score | -72.51 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -72.6 | |||||
| 3-Year EPS without NRI Growth Rate | -69.1 | |||||
| 3-Year FCF Growth Rate | -81.3 | |||||
| 3-Year Book Growth Rate | -64.3 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 6-1 Month Momentum % | -53.95 | |||||
| 12-1 Month Momentum % | -33.96 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.87 | |||||
| Quick Ratio | 4.87 | |||||
| Cash Ratio | 3.34 | |||||
| Days Sales Outstanding | 121.67 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -3.8 | |||||
| Shareholder Yield % | 116.67 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -342716.67 | |||||
| Net Margin % | -446233.33 | |||||
| FCF Margin % | -351616.67 | |||||
| ROE % | -175.77 | |||||
| ROA % | -121.36 | |||||
| ROIC % | -261.46 | |||||
| ROC (Joel Greenblatt) % | -364.98 | |||||
| ROCE % | -160.03 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 216 | |||||
| PB Ratio | 3.6 | |||||
| Price-to-Tangible-Book | 3.61 | |||||
| EV-to-EBIT | -0.44 | |||||
| EV-to-EBITDA | -0.47 | |||||
| EV-to-Revenue | 1872 | |||||
| EV-to-FCF | -0.49 | |||||
| Price-to-Net-Current-Asset-Value | 3.61 | |||||
| Price-to-Net-Cash | 5.93 | |||||
| Earnings Yield (Greenblatt) % | -227.27 | |||||
| FCF Yield % | -131.92 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Alaunos Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.006 | ||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 80.07 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0.112143 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | -33.96 | ||
| 52-Week Range (€) | 1.19 - 4.78 | ||
| Shares Outstanding (Mil) | 215.56 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Alaunos Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Alaunos Therapeutics Inc Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Alaunos Therapeutics Inc Frequently Asked Questions
What is Alaunos Therapeutics Inc(STU:WEK)'s stock price today?
The current price of STU:WEK is €1.66. The 52 week high of STU:WEK is €4.78 and 52 week low is €1.19.
When is next earnings date of Alaunos Therapeutics Inc(STU:WEK)?
The next earnings date of Alaunos Therapeutics Inc(STU:WEK) is 2024-08-14 Est..
Does Alaunos Therapeutics Inc(STU:WEK) pay dividends? If so, how much?
Alaunos Therapeutics Inc(STU:WEK) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers